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Abstract
Background and objective: Gastroesophageal reflux disease (GORD) is highly prevalent in idiopathic pulmonary
fibrosis (IPF) and may play a role in its pathogenesis. Recent IPF treatment guidelines suggest that all patients with
IPF be considered for antacid therapy. However, emerging evidence suggests that antacid therapy does not
improve IPF patient outcomes and may increase the risk of pulmonary infection.
Methods: Using prospectively collected data from the Australian IPF Registry including use of antacid therapy,
GORD diagnosis and GORD symptoms, the relationship of these GORD variables to survival and disease progression
was assessed. The severity of GORD symptoms using the frequency scale for symptoms of GORD (FSSG) and
its relationships to outcomes was also assessed for the first time in an IPF cohort.
Results: Five hundred eighty-seven (86%) of the 684 patients in the Australian IPF Registry were eligible for
inclusion. Patients were mostly male (69%), aged 71.0 ± 8.5 years with moderate disease (FVC 81.7 ± 21.5%;
DLco 48.5 ± 16.4%). Most patients were taking antacids (n = 384; 65%), though fewer had a diagnosis of GORD
(n = 243, 41.4%) and typical GORD symptoms were even less common (n = 171, 29.1%). The mean FSSG score
was 8.39 ± 7.45 with 43% (n = 251) having a score > 8. Overall, there was no difference in survival or disease
progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms.
Conclusions: Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes
in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients
and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.
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Introduction
Despite recent treatment advances [1, 2], idiopathic
pulmonary fibrosis (IPF) remains an irreversible fibrotic
lung disease associated with a poor survival [3]. While
IPF is limited to the lungs, co-morbidities are common
in this population and many studies have shown that
gastroesophageal reflux (GOR) is highly prevalent [4–7],
may contribute to pathogenesis and is reported to be asso-
ciated with a better survival [8, 9]. Gastroesophageal reflux
disease (GORD) is defined as the presence of troublesome
gastroesophageal reflux symptoms (at least twice a week)
and/or complications including oesophageal injury
[10, 11]. However, given the subjective nature of
symptoms, the accurate diagnosis of GORD remains
elusive. While objective testing for oesophageal injury
at endoscopy can be performed, there is poor correl-
ation with reflux symptoms. Only 39% of patients with
oesophageal injury reported typical reflux symptoms
in one study, and more than 60% of patients who
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reported reflux symptoms had no evidence of oesophageal
injury [12]. Twenty four hour ambulatory pH has also been
used as an objective measure of GOR, although only 25%
of patients with abnormal acid reflux on testing reported
typical GORD symptoms [7]. Additionally, ambulatory pH
monitoring cannot detect the presence of non-acid reflux,
which may have important clinical implications, further
limiting the utility of this test.
Current IPF treatment guidelines make a conditional
recommendation for considering antacid therapy for all
IPF patients irrespective of GORD symptoms [13]. This
was based on early retrospective data demonstrating im-
proved survival [8] and slowing disease progression [14]
in IPF patients on antacid therapy. Subsequent post-hoc
analyses from both the pirfenidone [15, 16] and ninteda-
nib [17] studies, have demonstrated no benefit of antacid
therapy on longer term outcomes for either the placebo
[15] or treatment [16] populations, calling into question
this recommendation.
Using data from the Australian IPF Registry, we
explored: 1) the use of antacid therapy in our IPF popu-
lation; and 2) the presence of GORD symptoms and dis-
ease, on disease progression and survival. For the first
time in IPF, we also utilised the frequency scale for
symptoms of GORD (FSSG) which was developed to
predict the presence of endoscopic features and severity
of oesophagitis resulting from GORD [18]. If clinically
meaningful, this questionnaire may be a simple way to




All participants from the Australian IPF Registry who
had completed questionnaires regarding co-morbidities,
treatment and reflux symptoms were included in the
study. The Australian IPF Registry is a prospective na-
tional registry which was established in 2012 for patients
with IPF across Australia. Demographic, questionnaire
and objective investigational data are collected at base-
line and six-monthly during follow up. Details of the
Registry have been published previously [19]. The data
analysis for this study has ethical approval from the
Sydney Local Health District ethics committee (protocol
number X14–0264).
GORD related variables
In the baseline Registry questionnaire, all Registry partic-
ipants are routinely asked about the following:
1. Diagnosis of GORD (Yes/No)
2. Typical GORD symptoms of heartburn, reflux or
sour taste in mouth after eating (Yes/No)
3. List of current medications
4. Frequency scale for the symptoms of GORD (FSSG)
(Table 1). A symptom score of > 8/48 was used to
define significant symptoms in categorical analysis
based on previously reported data regarding accuracy
in diagnosing endoscopic oesophagitis [18].
Statistical analysis
Results are presented as mean ± standard deviation (SD),
median and interquartile range (IQR) or n (%) as appro-
priate. Comparisons between groups were made using
Student’s t test or chi squared. An unstructured, linear
mixed model with random intercepts and slopes was
used to calculate the annual decline in FVC % predicted.
Survival analysis was performed with Cox proportional
hazards and Kaplan Meier methodology. All results with
a p value < 0.05 are reported as significant.
Results
Baseline characteristics
Of the 684 patients in the Registry at the time of this ana-
lysis, 587 (86%) patients had completed the baseline ques-
tionnaire. The characteristics of this population were
typical for IPF with most patients being older (71.0 ± 8.5
years), mostly male (n = 406; 69%) and ex/current smokers
(n = 424; 72%) (Table 2). The majority of patients were
taking antacid therapy (n = 384; 65%) at the time of entry
into the Registry, with most receiving proton pump inhibi-
tors (PPIs) (n = 344, 90.0%), and fewer receiving
Histamine-2 receptor antagonists (H2RA) (n = 10, 2.6%)
and a small proportion on both PPIs and H2RAs (n = 30,
7.8%). Of those receiving antacid treatment, 193 patients
(50%) had significant symptoms (FSSG> 8) while 191 pa-
tients (50%) reported less significant reflux symptoms
(FSSG≤8). The self-reported prevalence of GORD was
41.4% (n = 243) but only 29.1% (n = 171) reported typical
symptoms of “heartburn, reflux or sour taste in mouth
after eating”. The mean FSSG score was 8.39/48 (SD 7.45),
with 43% (n = 251) patients having a FSSG score > 8.
Disease progression and overall survival
During a median follow up period of 2.2 years (IQR 1.3
to 3.4 years), 240 (40.9%) patients died and 33 (5.6%)
had a lung transplant.
There was no difference in the annual fall in FVC
%predicted demonstrated, regardless of whether patients
were receiving antacid therapy (compared to those not
on therapy), or had a GORD diagnosis (compared to
those without a diagnosis of GORD), or had significant
GORD symptoms (FSSG> 8) (compared to those without
significant GORD symptoms (FSSG ≤8) (Table 3).
On univariable analysis for mortality, there was also
no difference between patients who were receiving ant-
acid treatment compared to those not receiving antacid
treatment (Table 4). There was also no association
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between the presence of a GORD diagnosis or significant
GORD symptoms with overall survival (Fig. 1).
On multivariable analysis, there was no difference in
survival between antacid therapy groups HR= 1.02; 95% CI
0.72–1.43; p = 0.928), adjusting for age, gender, smoking,
FVC %predicted and DLco %predicted. Increasing age, re-
ducing FVC %predicted and DLco %predicted levels, were
independent predictors of worse overall survival.
In the subgroup of 384 patients receiving antacid therapy,
there was also no difference in survival (HR = 0.88, 95% CI
= 0.64,1.20; p = 0.415) between those with significant
GORD symptoms (FSSG> 8), compared to those without
(FSSG≤8) significant GORD symptoms (Fig. 2). There was
also no difference in survival based on GORD diagnosis or
typical GORD symptoms.
Discussion
This is one of the largest retrospective cohort studies of
antacid therapy in IPF and is the first study to utilise the
FSSG score to assess GORD symptom severity in pa-
tients with IPF. In this analysis of real-world IPF patients
from the Australian IPF Registry, treatment with antacid
therapy did not have any impact on either IPF disease
progression or survival, regardless of the presence of
Table 1 Frequency scale for the symptoms of GORD (FSSG)
Never Occasionally Sometimes Often Always
1. Do you get heartburn? 0 1 2 3 4
2. Does your stomach get bloated? 0 1 2 3 4
3. Does your stomach ever feel heavy after meals? 0 1 2 3 4
4. Do you sometimes subconsciously rub your chest with your hand? 0 1 2 3 4
5. Do you ever feel sick? 0 1 2 3 4
6. Do you get heartburn after meals? 0 1 2 3 4
7. Do you have an unusual (eg burning) sensation in your throat? 0 1 2 3 4
8. Do you feel full while eating meals? 0 1 2 3 4
9. Do some things get stuck when you swallow? 0 1 2 3 4
10. Do you get bitter liquid (acid) coming up into your throat? 0 1 2 3 4
11. Do you burp a lot? 0 1 2 3 4
12. Do you get heartburn if you bend over? 0 1 2 3 4
Total Acid reflux symptoms (total = 48)
Total Dyspeptic (dysmotility) symptoms (total = 20)
Total Dyspeptic (dysmotility) symptoms are in bold
Table 2 Clinical characteristics and prevalence of GORD related features
n overall SD or % antacid no antacid p
587 384 65% 203 35%
Age 586 71.0 8.5 71.6 8.2 69.7 8.8 0.008
male 587 406 69% 258 67% 148 73% NS
Ever smoker 587 424 72% 280 73% 144 75% NS
BMI 450 28.9 4.8 28.8 4.5 29.0 5.4 NS
FVC (L) 462 2.6 0.8 2.6 0.77 2.6 0.76 NS
FVC (%pred) 462 81.7% 21.4% 83.6% 22.6% 78.3% 18.8% 0.009
DLco (%pred) 409 48.5% 16.4% 49.8% 16.1% 46.1% 16.6% 0.027
CPI 405 44.93 13.88 43.83 14.16 46.87 13.19 0.034
SGRQ 550 47.6 20.5 48.57 20.5 45.2 20.7 0.072
FSSG symptom score 587 8.4 7.5 9.7 7.9 5.9 5.7 < 0.001
GORD typical symptoms 587 171 29% 139 36% 32 16% < 0.001
GORD disease 587 243 41% 208 54% 35 17% < 0.001
FSSG > 8 587 251 43% 193 50% 58 29% < 0.001
BMI Body Mass Index, FVC Forced Vital Capacity, DLco diffusion capacity for carbon monoxide, CPI composite physiological index, GORD gastroesophageal reflux
disease, SGRQ St George’s Respiratory Questionnaire, FSSG frequency scale for the symptoms of GORD
Jo et al. BMC Pulmonary Medicine           (2019) 19:84 Page 3 of 7
reflux symptoms. There was also no association between
either the presence of typical reflux symptoms nor symp-
tom severity with IPF disease progression or survival. In
the absence of prospective, randomised controlled trials
showing benefit of antacid medications in IPF, this study
suggests that antacid therapy should not be recommended
broadly for the treatment of IPF patients.
There has been extensive debate regarding the utility of
antacid therapy in IPF. A retrospective analysis of 204 pa-
tients by Lee et al. [8] showed that reported use of antacid
therapy was associated with decreased radiological fibrosis
and was an independent predictor of longer survival. Pa-
tients with typical reflux symptoms (heartburn or regurgita-
tion) as well as those with patient or physician reported
GORD diagnosis, were also found to have improved sur-
vival [8]. Unlike the study by Lee et al. [8], our study of 587
IPF patients did not show any association between GORD
diagnosis, reflux symptoms or antacid therapy with survival.
Similar to the post-hoc analysis of the 624 patients on pla-
cebo [15] and 623 patients on pirfenidone [16], we found
that there was no difference in disease progression or sur-
vival in patients on antacid therapy. This however, is in con-
trast to the post-hoc analysis of 242 patients from the
IPFnet trials which showed patients on antacid therapy had
a slower decline in FVC [14]. In a recent meta-analysis
[20], treatment of GORD was associated with a reduction
in IPF-related mortality but not all cause mortality. The
authors report however, that the quality of evidence was
low and was based on 3 studies [15, 16, 21]. Given the
Table 3 Annual decline in FVC% predicted by GORD variable
GORD variable Yes (95% CI) No (95% CI) p
Antacid therapy 4.0% 3.3, 4.8% 3.7% 2.7, 4.7% 0.614
GORD diagnosis 4.6% 3.5, 5.4% 3.5% 2.7, 4.4% 0.162
Typical reflux symptoms 4.0% 3.0, 5.1% 3.7% 3.0, 4.4% 0.612
FSSG> 8 4.5% 3.5, 5.4% 3.5% 2.7, 4.4% 0.153
Table 4 Univariable Cox analysis for Overall
HR 95% CI P
Age 1.03 1.01 1.04 0.001
male 1.34 1.01 1.79 0.043
smoker 1.39 1.03 1.87 0.032
BMI 0.95 0.92 0.98 0.002
FVC % predicteda 0.78 0.72 0.84 < 0.001
DLco % predicteda 0.56 0.5 0.63 < 0.001
GORD treatment 0.99 0.75 1.31 NS
GORD typical symptoms 0.88 0.66 1.16 NS
GORD disease 1.07 0.83 1.39 NS
FSSG score > 8 0.85 0.66 1.10 NS
afor every 10 unit change; BMI Body Mass Index, FVC Forced Vital Capacity,
DLco diffusion capacity for carbon monoxide, GORD gastroesophageal reflux
disease, FSSG frequency scale for the symptoms of GORD
Fig. 1 Kaplan Meier analysis for overall survival. a. Antacid therapy b.
Gastroesophageal disease diagnosis c. Frequency scale for the
symptoms of GORD (FSSG)
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conditional recommendation for antacid therapy in the
2011 and 2015 IPF treatment guidelines [13], our study
highlights the need for prospective randomised, controlled
studies in this controversial area.
The conflicting results surrounding antacid therapy in
IPF may reflect the contribution of non-acid reflux in
the pathogenesis of IPF. While it has been postulated
that micro-aspiration of acid results in lung injury,
refluxate in GORD also contains other potentially harm-
ful substances such as bile salts, enzymes and bacteria
[22]. A study of bronchoalveolar lavage (BAL) showed
an increase in pepsin and bile acids in patients with IPF
(n = 13/16) compared to patients with other interstitial
lung diseases (ILDs) (n = 5/20) and those with no ILD
(n = 0/16) [6]. Animal studies have shown that acid as-
piration can cause collagen deposition and disruption of
parenchymal architecture [23], while others have shown
parenchymal fibrosis in chronic aspiration is independ-
ent of acidity [24]. The reflux of non-acid substance may
not result in symptoms nor respond to antacid therapy,
while still causing lung injury and explain the lack of
association between symptoms and antacid treatment
with IPF outcomes.
Anti-reflux surgery would prevent the reflux of both
acid and non-acid refluxate and thus a prospective,
randomised controlled trial to compare the decline in
FVC between surgery and non-surgery groups has been
performed. In this study of 58 IPF patients, patients who
had surgery had a slower decline in FVC over 48 weeks
(50mLs) compared to those who did not have surgery
(130mLs). However this difference did not reach statistical
significance (p = 0.28), and has been ascribed possibly to
the small sample size [25]. With a recent meta-analysis of
case control studies suggesting that the association
between IPF and GORD may not be directly causal but be
explained by confounding factors, particularly with smok-
ing, the recommendation to broadly treat GORD in IPF is
further brought into question [26].
Another major problem facing the investigation of
the relationship between GORD and IPF is the subject-
ive nature of the GORD definition. While GORD is
defined as the presence of troublesome symptoms and/
or complications [11, 27], “troublesome symptoms” are
subjective and whether the presence of cough in IPF fits
this criteria is highly debatable [28]. In this study, we
used the standardised FSSG questionnaire to character-
ise the severity of reflux symptoms in patients with IPF.
The FSSG questionnaire was initially developed by
screening 50 symptom questions to a group of 124
patients with an endoscopic diagnosis of oesophagitis.
12 questions were then selected and validated in a
separate cohort of patients with and without GORD.
They reported a sensitivity of 62%, a specificity of 59%
and accuracy of 60% at a score of 8/48 for the presence
of endoscopically visible reflux oesophagitis [18]. The
relatively low accuracy of this score again reflects the
subjective nature of symptoms. That said, compared to
other studies where the rate of oesophagitis was 38.7% in
patients who had typical symptoms [12] and 21.4% in pa-
tients with a GORD diagnosis [21], the FSSG question-
naire appeared to have greater accuracy. Improvement in
endoscopic oesophagitis that were mirrored by improve-
ments in FSSG scores is also encouraging as to the utility
of this score [18]. In our study, there was no relationship
between this questionnaire and IPF outcomes, suggesting
that the FSSG questionnaire may be of use when consider-
ing treatment with antacid therapy for reflux oesophagitis
without the need for endoscopy, but is not helpful in
Fig. 2 Kaplan Meier analysis for overall survival in patients on antacid therapy by presence of symptoms
Jo et al. BMC Pulmonary Medicine           (2019) 19:84 Page 5 of 7
differentiating patients at greater risk for IPF disease pro-
gression or death.
Due to the retrospective nature of this study, there are
several limitations. Firstly, the diagnosis of GORD was
self-reported and may under or overestimate prevalence.
For this reason, we looked at many GORD related vari-
ables to assess the impact of GORD and GORD treat-
ment. Secondly, all antacid use was self-reported at
baseline and analysed using an intention to treat ap-
proach. This approach does not reflect ongoing use nor
quantify total exposure, which may be of clinical signifi-
cance. In a retrospective study of 786 IPF patients, the
use of PPIs for > 4 months was associated with reduced
mortality whereas use for 2 or 3months was not [21].
The introduction of categorisation by exposure duration
however introduces immortal time bias and may explain
some of the perceived benefit of therapy. A recent ana-
lysis by Tran et al. suggests that immortal time bias ac-
counts for the beneficial effect of antacid therapy in
many of the observational studies in IPF [29]. Thirdly, as
this was not a randomised trial, it may be possible that
patients who had the worst reflux were already on
long-term treatment, mitigating their risk for disease
progression. This may explain the fact that at baseline,
patients on treatment had better FVC %predicted and
DLco %predicted. There was however, no correlation
between the severity of reflux symptoms in patients not
on treatment and outcomes, suggesting that this is un-
likely to be a key factor determining prognosis. Finally,
the baseline characteristics between the treatment and
non-treatment groups differed with patients on treat-
ment tending to be older but have better lung function.
Multivariable analysis adjusting for age, gender, smoking
status, FVC and DLco however did not have any impact
on outcomes. Despite the limitations, this study is one
of the largest retrospective cohort studies of antacid
therapy in IPF. It is also the first study to utilise the
FSSG score, collected prospectively, in patients with IPF
and shows that GORD symptom severity does not pre-
dict decline.
Conclusion
While further, robust randomised controlled trials are still
needed, this study adds weight to the gathering evidence
that antacid therapy may not be beneficial in IPF patients
and that reflux directed therapy should be considered on
an individual basis. While the severity of reflux symptoms
does not predict IPF outcomes, it may help select patients
who will benefit from GORD treatment for management
of symptoms and the prevention of oesophageal injury.
Our study also highlights the difficulty in defining GORD
and highlights the need to standardise the GORD defin-
ition used in future prospective randomised studies if evi-
dence of treatment benefit is to be accurately assessed.
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